Literature DB >> 25052539

An eggshell-like mineralized recurrent lesion in the popliteal region after treatment of giant cell tumor of the bone with denosumab.

Keisuke Akaike1, Yoshiyuki Suehara, Tatsuya Takagi, Kazuo Kaneko, Tsuyoshi Saito.   

Abstract

We report a case of recurrent giant cell tumor of the bone (GCTB) in which treatment with denosumab gradually enhanced the eggshell-like mineralization at the periphery of the tumor. A 28-year-old male presented with a mass on his left distal femur that had enlarged within the past few months. Before curettage, GCTB of the distal femur was diagnosed based on histological analysis of a biopsy specimen; the tumor consisted of a proliferation of ovoid mononuclear stromal cells with evenly scattered multinucleated osteoclast-like giant cells. The tumor recurred three times after the initial diagnosis; at the time of the third relapse, the patient underwent en bloc resection and reconstruction with a knee joint prosthesis. He was also treated with denosumab postoperatively because some studies have recently shown the benefits of the receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitor denosumab as adjuvant therapy in patients with GCTB. Six months after starting adjuvant treatment with denosumab, radiography revealed a mineralized nodule >2 cm in diameter at the popliteal region; this lesion was considered a soft tissue recurrence of GCTB. Treatment with denosumab was continued for another 1.5 years, and the lesion was resected. Histological examination showed residual mononuclear stromal cells expressing RANKL without multinucleated giant cells surrounded by the peripheral mineralization. The patient was successfully treated by complete resection with the support of adjuvant treatment with denosumab.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25052539     DOI: 10.1007/s00256-014-1961-z

Source DB:  PubMed          Journal:  Skeletal Radiol        ISSN: 0364-2348            Impact factor:   2.199


  17 in total

1.  Recurrent giant-cell tumor presenting as a soft-tissue mass. A report of four cases.

Authors:  F Y Lee; M Montgomery; E J Hazan; S B Keel; H J Mankin; S Kattapuram
Journal:  J Bone Joint Surg Am       Date:  1999-05       Impact factor: 5.284

2.  Ossified soft tissue recurrence of giant cell tumor of bone.

Authors:  S Ehara; J Nishida; M Abe; Y Kawata; H Saitoh; S V Kattapuram
Journal:  Clin Imaging       Date:  1992 Jul-Sep       Impact factor: 1.605

3.  Extraosseous primary and recurrent giant cell tumors: transforming growth factor-beta1 and -beta2 expression may explain metaplastic bone formation.

Authors:  L A Teot; R J O'Keefe; R N Rosier; J X O'Connell; E J Fox; D G Hicks
Journal:  Hum Pathol       Date:  1996-07       Impact factor: 3.466

4.  Denosumab treatment of metastatic giant-cell tumor of bone in a 10-year-old girl.

Authors:  Nicole A Karras; Lynda E Polgreen; Christian Ogilvie; J Carlos Manivel; Keith M Skubitz; Emily Lipsitz
Journal:  J Clin Oncol       Date:  2013-03-18       Impact factor: 44.544

5.  Primary giant cell tumor of soft tissues: a study of 22 cases.

Authors:  A M Oliveira; A P Dei Tos; C D Fletcher; A G Nascimento
Journal:  Am J Surg Pathol       Date:  2000-02       Impact factor: 6.394

6.  Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.

Authors:  David Thomas; Robert Henshaw; Keith Skubitz; Sant Chawla; Arthur Staddon; Jean-Yves Blay; Martine Roudier; Judy Smith; Zhishen Ye; Winnie Sohn; Roger Dansey; Susie Jun
Journal:  Lancet Oncol       Date:  2010-02-10       Impact factor: 41.316

7.  Giant cell tumors of soft tissue: a clinicopathologic study of 18 benign and malignant tumors.

Authors:  J X O'Connell; B M Wehrli; G P Nielsen; A E Rosenberg
Journal:  Am J Surg Pathol       Date:  2000-03       Impact factor: 6.394

8.  p53 mutations may be involved in malignant transformation of giant cell tumor of bone through interaction with GPX1.

Authors:  Taketo Okubo; Tsuyoshi Saito; Hiroyuki Mitomi; Tatsuya Takagi; Tomoaki Torigoe; Yoshiyuki Suehara; Kazuo Kaneko; Takashi Yao
Journal:  Virchows Arch       Date:  2013-06-08       Impact factor: 4.064

9.  Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.

Authors:  Daniel G Branstetter; Scott D Nelson; J Carlos Manivel; Jean-Yves Blay; Sant Chawla; David M Thomas; Susie Jun; Ira Jacobs
Journal:  Clin Cancer Res       Date:  2012-06-18       Impact factor: 12.531

10.  Radiological and pathological characteristics of giant cell tumor of bone treated with denosumab.

Authors:  Michiyuki Hakozaki; Takahiro Tajino; Hitoshi Yamada; Osamu Hasegawa; Kazuhiro Tasaki; Kazuo Watanabe; Shinichi Konno
Journal:  Diagn Pathol       Date:  2014-06-07       Impact factor: 2.644

View more
  10 in total

1.  Visualization of hidden soft-tissue recurrence of giant cell tumor of bone enabled by preoperative denosumab treatment: a case description.

Authors:  Takeo Suzuki; Yoichi Kaneuchi; Michiyuki Hakozaki; Hitoshi Yamada; Shoki Yamada; Shinichi Konno
Journal:  Quant Imaging Med Surg       Date:  2021-08

2.  Disappearance of giant cells and presence of newly formed bone in the pulmonary metastasis of a sacral giant-cell tumor following denosumab treatment: A case report.

Authors:  Tetsuro Yamagishi; Hiroyuki Kawashima; Akira Ogose; Taro Sasaki; Tetsuo Hotta; Shoichi Inagawa; Hajime Umezu; Naoto Endo
Journal:  Oncol Lett       Date:  2015-11-04       Impact factor: 2.967

Review 3.  Denosumab in Patients with Giant Cell Tumor and Its Recurrence: A Systematic Review.

Authors:  Khodamorad Jamshidi; Mohamad Gharehdaghi; Sami Sam Hajialiloo; Masoud Mirkazemi; Kamran Ghaffarzadehgan; Azra Izanloo
Journal:  Arch Bone Jt Surg       Date:  2018-07

Review 4.  RANK pathway in giant cell tumor of bone: pathogenesis and therapeutic aspects.

Authors:  Pan-Feng Wu; Ju-yu Tang; Kang-hua Li
Journal:  Tumour Biol       Date:  2015-01-25

5.  Protein Expression Profiling of Giant Cell Tumors of Bone Treated with Denosumab.

Authors:  Kenta Mukaihara; Yoshiyuki Suehara; Shinji Kohsaka; Keisuke Akaike; Yu Tanabe; Daisuke Kubota; Midori Ishii; Tsutomu Fujimura; Saiko Kazuno; Taketo Okubo; Tatsuya Takagi; Takashi Yao; Kazuo Kaneko; Tsuyoshi Saito
Journal:  PLoS One       Date:  2016-02-10       Impact factor: 3.240

Review 6.  Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone.

Authors:  Czar Louie Gaston; Robert J Grimer; Michael Parry; Silvia Stacchiotti; Angelo Paolo Dei Tos; Hans Gelderblom; Stefano Ferrari; Giacomo G Baldi; Robin L Jones; Sant Chawla; Paolo Casali; Axel LeCesne; Jean-Yves Blay; Sander P D Dijkstra; David M Thomas; Piotr Rutkowski
Journal:  Clin Sarcoma Res       Date:  2016-09-14

7.  Giant cell tumour of the distal radius/ulna: response to pre-operative treatment with short-term denosumab.

Authors:  Catherine L McCarthy; Christopher L M H Gibbons; Kevin M Bradley; A Bass Hassan; Henk Giele; Nicholas A Athanasou
Journal:  Clin Sarcoma Res       Date:  2017-11-30

8.  Soft tissue recurrence of giant cell tumor of the bone: Prevalence and radiographic features.

Authors:  Leilei Xu; Jing Jin; Annan Hu; Jin Xiong; Dongmei Wang; Qi Sun; Shoufeng Wang
Journal:  J Bone Oncol       Date:  2017-09-20       Impact factor: 4.072

Review 9.  Radiological findings of denosumab treatment for giant cell tumours of bone.

Authors:  Kirsten van Langevelde; Catherine L McCarthy
Journal:  Skeletal Radiol       Date:  2020-04-26       Impact factor: 2.199

10.  Denosumab for Effective Tumor Size Reduction in Patients With Giant Cell Tumors of the Bone: A Systematic Review and Meta-Analysis.

Authors:  Josef Yayan
Journal:  Cancer Control       Date:  2020 Jul-Aug       Impact factor: 3.302

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.